Catalym.com Login
Searching for the Catalym.com login page? Here you will find the most up-to-date links to login pages related to catalym.com. Also, we have collected additional information about catalym.com login for you below.
| Category | C |
|---|---|
| Domain name | catalym.com |
| DNS servers | ns1078.ui-dns.de,ns1078.ui-dns.biz,ns1078.ui-dns.org,ns1078.ui-dns.com |
| IP | 217.160.0.210 |
| Country by IP | DE |
| Country by HTML code | DE |
| Web server type | Apache |
| Hostname | 217-160-0-210.elastic-ssl.ui-r.com |
| Emails | christian.wallasch@catalym.com,info@catalym.com |
| Alexa traffic rank | 988830 |
| Phone numbers | +49-176-52840376 |
Catalym – Catalyzing Immunotherapy
CatalYm is a pioneer in translating the therapeutic potential of neutralizing GDF-15 into meaningful clinical responses for patients with solid tumors. About Us Catalym Corporate Video How we neutralize GDF-15 within the tumor microenvironment Click to see the movie. Our latest news & where to connect March 1, 2022 Visit website
CatalYm Commences Phase 2 Development of GDF-15-Targeting …
CatalYm receives International Nonproprietary Name (INN) visugromab for CTL-002 as approved by the World Health Organization Munich, Germany, March 01, 2022 – CatalYm today announced treatment of the first patients in a series of phase 2a cohorts targeting solid tumors, initiating phase 2 development of CTL-002. Visit website
Catalym - Crunchbase Company Profile & Funding
Catalym develops antibodies against a placental factor which is overexpressed by various tumour types. Munich, Bayern, Germany 11-50 Series B Private www.catalym.com/ 42,645 Highlights Total Funding Amount $59.3M Employee Profiles 5 Investors 6 Similar Companies 6 Details Industries Therapeutics Headquarters Regions European Union (EU) Visit website
CatalYm Commences Phase 2 Development of GDF-15-Targeting …
- CatalYm receives International Nonproprietary Name (INN) visugromab for CTL-002 as approved by the World Health Organization MUNICH, March 01, 2022 -- ( BUSINESS WIRE )-- CatalYm today announced... Visit website
CatalYm Company Profile - Office Locations, Competitors ... - Craft
CatalYm is a biopharmaceutical company developing cancer immunotherapies. It develops monoclonal antibodies that enhance the effective infiltration of immune cells into the microenvironment of cold tumors, addressing a high unmet medical need in immuno-oncology. The company aims to improve cancer patient survival and quality of life. Healthcare Visit website
CatalYm Appoints Dr. Phil L’Huillier as CEO
CatalYm GmbH Am Klopferspitz 19 82152 Martinsried, Planegg Germany www.catalym.com info@catalym.com Media Inquiries MC Services AG Katja Arnold, Julia von Hummel, Shaun Brown T: +49 (0)89 2102280 catalym@mc-services.eu Download this press release as PDF file [139 kB] Share this Visit website
CatalYm Presents Updated Tolerability and Preliminary …
MUNICH, October 11, 2021 -- ( BUSINESS WIRE )-- CatalYm, today announced an update from the dose escalation part of the ongoing first-in-human trial "GDFather" ( GDF-15 Antibody-mediated Effector... Visit website
CatalYm Presents Expanded Clinical and New Preclinical Data from
CatalYm has identified GDF-15 as a central regulator of the immune system in the tumor microenvironment. We are pioneering the reversal of GDF-15-mediated immunosuppression to induce a potent antitumoral immune reaction in non-responsive tumors. CatalYms lead program visugromab (CTL-002) is poised to demonstrate clinical proof-of … Visit website
CatalYm Commences Phase 2 Development of GDF-15-Targeting …
About CatalYm CatalYm has identified GDF-15 as a central regulator of the immune system in the tumor microenvironment. We are pioneering the reversal of GDF-15-mediated immunosuppression to induce a potent antitumoral immune … Visit website
CatalYm: Antibody GDF-15 CTL-002 - Vesalius Biocapital III
Munich, Germany, March 1st, 2022 – CatalYm today announced treatment of the first patients in a series of phase 2a cohorts targeting solid tumors, initiating phase 2 development of CTL-002. The trial will evaluate the safety and efficacy of the companys lead product candidate, the GDF-15 neutralizing antibody CTL-002 (visugromab), at the ... Visit website
CatalYm Appoints Industry Leader Dr. Phil L’Huillier as
CatalYm received financial support from the EIF via the EIB-EIF Co-investment Facility, backed by the European Union through the European Fund for Strategic Investments (EFSI). Contact CatalYm GmbH... Visit website
CatalYm Commences Phase 2 Development of GDF-15-Targeting …
Munich, Germany, March 1, 2022 – CatalYm today announced treatment of the first patients in a series of phase 2a cohorts targeting solid tumors, initiating phase 2 development of CTL-002. The trial will evaluate the safety and efficacy of the company’s lead product candidate, the GDF-15 neutralizing antibody CTL-002 (visugromab), at the confirmed … Visit website
CatalYm GmbH - Company Profiles - BCIQ
For the biopharma industry investment, business development and competitive intelligence professionals who require information to support financing, partnering and licensing activities, BCIQ provides accurate information and context to support profitable and strategic decision making. Unlike other intelligence solutions, BCIQ exclusively supports the unique needs of the … Visit website
CatalYm Presents Expanded Clinical and New Preclinical Data …
MUNICH,, November 12, 2021--CatalYm today announced the presentation of expanded clinical and new preclinical data for its lead candidate CTL-002, an antibody targeting the novel cancer target GDF ... Visit website
Catalym.com Login Guide
Catalym.com Login Requirements
- Catalym.com login page link (you can find on this page above);
- catalym.com login correct username, password, or email if necessary;
- Internet browser, which will open the catalym.com login page, if the page does not open, please use a VPN.
How to Login in catalym.com? 4 Easy Steps:
- Open your browser and follow one of the official catalym.com links above.
- On the page, find the "Login" button, usually located at the top right of the screen.
- The page will ask you to enter your catalym.com account and password in the appropriate fields. Sometimes you will need to enter an email address instead of an account. In rare cases, the site will ask you to pass the captcha, this is done to check if you are a bot or not.
- Then press the login button, if you entered your login information correctly, you will be taken to your catalym.com profile page. Good luck :)
Add review
